Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer
出版年份 2016 全文链接
标题
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer
作者
关键词
-
出版物
EXPERT OPINION ON EMERGING DRUGS
Volume 21, Issue 3, Pages 267-282
出版商
Informa UK Limited
发表日期
2016-08-10
DOI
10.1080/14728214.2016.1220535
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours
- (2016) Andrew Rowland et al. EUROPEAN JOURNAL OF CANCER
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
- (2015) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- BRAFcodons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
- (2015) C. Cremolini et al. ANNALS OF ONCOLOGY
- A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
- (2015) H. Hagman et al. ANNALS OF ONCOLOGY
- Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
- (2015) T Macarulla et al. BRITISH JOURNAL OF CANCER
- Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
- (2015) Alessio Amatu et al. BRITISH JOURNAL OF CANCER
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
- (2015) R. Yaeger et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer
- (2015) Khanh Do et al. Clinical Colorectal Cancer
- Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
- (2015) Guillem Argilés et al. EUROPEAN JOURNAL OF CANCER
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
- (2015) Christophe Tournigand et al. LANCET ONCOLOGY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- The genomic landscape of response to EGFR blockade in colorectal cancer
- (2015) Andrea Bertotti et al. NATURE
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for ‘Off-Target' Effects Not Mediated by c-Met Inhibition
- (2015) Clemens Reuther et al. NEUROENDOCRINOLOGY
- Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors
- (2015) Cinta Hierro et al. SEMINARS IN ONCOLOGY
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
- (2015) S. M. Kavuri et al. Cancer Discovery
- Gastrointestinal malignancies harbor actionable MET exon 14 deletions
- (2015) Jeeyun Lee et al. Oncotarget
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
- (2015) J. Randolph Hecht et al. Cancer Management and Research
- O-0019 * CALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON
- (2014) A. Venook et al. ANNALS OF ONCOLOGY
- Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
- (2014) E Samalin et al. BRITISH JOURNAL OF CANCER
- Colorectal cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
- (2014) H. S. Hochster et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer
- (2014) Bert H. O'Neil et al. Clinical Colorectal Cancer
- A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer
- (2014) Tamas Hickish et al. EUROPEAN JOURNAL OF CANCER
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
- (2014) Alain R Thierry et al. NATURE MEDICINE
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
- (2013) A. Johnsson et al. ANNALS OF ONCOLOGY
- Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
- (2013) M. Peeters et al. ANNALS OF ONCOLOGY
- Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study
- (2013) Jeffrey R. Infante et al. CANCER
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
- (2013) J. Tabernero et al. CLINICAL CANCER RESEARCH
- Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
- (2013) S. A. Flanigan et al. CLINICAL CANCER RESEARCH
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
- (2013) Johanna C. Bendell et al. Clinical Colorectal Cancer
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- (2013) Alfredo Carrato et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
- (2013) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study
- (2012) Yasushi Tsuji et al. CANCER SCIENCE
- Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
- (2012) Andrew J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
- (2012) Paulo M. Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
- (2012) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Molecular Predictors of Response to Antiangiogenesis Therapies
- (2011) Armin Gerger et al. CANCER JOURNAL
- Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer
- (2011) Leonard Saltz et al. Clinical Colorectal Cancer
- Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
- (2011) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab
- (2010) Vincenzo Formica et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
- (2010) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
- (2009) J Souglakos et al. BRITISH JOURNAL OF CANCER
- A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
- (2008) A. Santoro et al. ANNALS OF ONCOLOGY
- PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer
- (2008) Yoshito Nakamura et al. ANNALS OF SURGICAL ONCOLOGY
- A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer
- (2008) G. A. Fisher et al. CLINICAL CANCER RESEARCH
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started